Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRADAII: Atazanavir/Dolutegravir/Lamivudine Maintenance in HIV
NCT02566707Phase 2Terminated
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of atazanavir, dolutegravir, lamivudine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Radboud University Medical Center. Started Aug 2015; status: terminated.
02
Drugs
atazanavirdolutegravirlamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02566707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02566707.